

Illuminating Lupus

Systemic Lupus Erythematosus in American Indian/ Alaska Native Population

Signs and symptoms for early recognition

Welcome.

We are excited to speak with you today about lupus.

Before we get started...

ACCREDITATION STATEMENT

The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

DESIGNATION STATEMENT

The ACR designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

USE OF PROFESSIONAL JUDGMENT

This activity, including all educational links, is intended to be used as a tool to assess the base knowledge of the learner. The information presented relates to basic

principles of diagnosis and therapy, and is meant in no way to substitute for an individual patient assessment based upon the healthcare provider's examination of the patient and consideration of laboratory data and other factors unique to the patient.

DRUGS AND DOSES

When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

ACR DISCLOSURE STATEMENT

The American College of Rheumatology is an independent, professional organization that does not endorse specific procedures or products of any pharmaceutical/biotech concern.

SUPPORT

The project described was supported by Grant number 6 NU58DP007138; CFDA number 93.078, *Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships*. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the HHS, CDC.

FACULTY REPORTED DISCLOSURES

[To be filled in]

Pre and post assessment

This assessment is voluntary and used solely to rate the quality of this seminar.

No individual data will be shared as a part of this project. We will use your unique identifier only to match the assessments for analysis. Final data will be reported in aggregate form.

①

PRE-ASSESSMENT (BEFORE SEMINAR)

- 10 multiple choice or true/false questions and 1 efficacy question
- Additional demographic questions

②

POST-ASSESSMENT (AFTER SEMINAR)

- Repeat pre-assessment
- Additional qualitative questions

Thank you.

We appreciate your time in taking our pre-seminar assessment. Create a unique assessment identifier by completing your: initials, first three letters of last name, birth year (YYYY) and state.

Please write legibly so we can match and use the data.

Learning objectives

After this presentation, you should:



Recognize the signs and symptoms of lupus.



Know when to effectively refer a suspected lupus case to a rheumatologist.




Know how to initiate a work-up for lupus.



Have increased knowledge about lupus epidemiology, health disparities and disease characteristics in the AI/AN community and other racial/ethnic populations.


We've all heard the expression,
when you hear hoof beats
think horses,
not zebras.



In many cases, lupus is a zebra.

With a worldwide prevalence of 140 out of 100,000, lupus is likely not the reason the woman in your office has a fever and fatigue.¹

But when the person you are treating is a **woman of color in her childbearing years**, that unexplained, prolonged fever has a greater likelihood of being one indicator of lupus.



AI/AN women have the **second highest** prevalence of lupus among women of color.

For AI/AN persons, lupus has a prevalence of 178 cases per 100,000 person years. AI/AN persons develop lupus at 10x the rate of Caucasians.

Among AI/AN women, the prevalence of lupus is significantly higher among women than men at 271 cases per 100,000.

Prevalence of lupus was found to be highest among women from 50-59 years old.²



African American women have the highest prevalence of lupus, followed by AI/AN women.

In the United States, lupus affects:

- 400 cases per 100,000 for African American women;
- 271 cases per 100,000 for AI/AN women.
- 142.7 per 100,000 in Hispanic / Latino women.
- 118.7 per 100,000 for Asian women.³

271
100,000



A recent study⁴ shows that AI/AN persons experience SLE activity at **higher rates** than other racial/ethnic minorities.



Have a higher prevalence of SLE (up to 1.7 times)



Suffer more damage accrual, including about 40 percent that suffer from renal disorder



Have higher disease activity scores by the SLE disease activity index



Experience higher SLE mortality rates



Experience earlier on-set of lupus

Meet Ivana
and Michelle.



A lupus diagnosis can take as long as **two or more years** and include visits to three or more health care providers.



Why is the diagnosis of lupus so challenging?

LUPUS IS:

- the great masquerader
- can mimic other conditions like viral syndromes, malignancies, allergic reactions and stress
- sometimes associated with depression or fibromyalgia

SYMPTOMS MAY BE VAGUE, INCLUDING:

- fatigue
- achiness
- stiffness
- low-grade fever
- swollen lymph nodes
- rashes

SYMPTOMS MAY:

- develop slowly
- come on suddenly

Ivana describes
the difficulty in
being accurately
diagnosed.



This delay in diagnosis can be **devastating** for a person with lupus.

THIS COULD LEAD TO:

- organ failure
- a five-fold increased risk of death

With an early diagnosis, the chances of a person with lupus living a full life with a manageable, chronic disease are increased.⁵



Specific racial and ethnic minorities with lupus have mortality rates at least **three times as high** as white individuals, often because they are poor and do not have access to primary-care doctors and specialists who can diagnose and treat them.⁶

In nationwide Medicaid dataset, adjusted hazard ratio for all-cause mortality in SLE patients was high in these groups:

- AI/AN 1.40 (95% CI 1.04–1.90)
- Black 1.21 (95% CI 1.10–1.33)
- Reference group was white, lower rates of mortality in Hispanics and Asians with SLE



A person who is feeling sick will often seek help from a primary care provider or emergency room at the onset of the symptoms.

It is crucial that these providers recognize potential symptoms of lupus and make referrals to rheumatologists when appropriate.



Healthcare limitations in the AI/AN community can significantly impact access to adequate rheumatological care.

- Level of provider education on lupus
- Distance from a rheumatologist, education and IHS funding



Level of provider education

The amount of training providers receive in medical school varies widely, with some students receiving **only 90 minutes** of education on lupus.



Distance from rheumatologist

- Many AI/AN persons living in rural and remote areas don't have easy access to a rheumatologist for full diagnosis and treatment, even if their primary doctor suspects lupus.
- Rheumatologist can be hundreds of miles away.
- Transportation cost are significant for many AI/AN person.



It is our mission to educate primary care providers about lupus, so people with lupus can get the correct referral, diagnosis and treatment they need.

Michelle describes
her experience in
being diagnosed.




Let's review some of the symptoms of and challenges related to the diagnosis of lupus.

About systemic lupus erythematosus (SLE)

- Lupus is an inflammatory, multi-system, autoimmune disease of unknown etiology with clinical manifestations that can change frequently and unexpectedly and suggestive laboratory manifestations.
- Lupus can be mild, severe and anything in between.
- The diversity of clinical symptoms is great, and all organ systems are vulnerable.
- Lupus is characterized by periods of flare and remission and can culminate in irreversible, end-stage organ damage.

Pathogenesis of lupus

- Autoimmunity is an altered immune homeostasis that leads to auto-reactivity, immunodeficiency and malignancy.
- Immune dysregulation leading to auto-reactivity and autoantibodies in lupus occurs in different phases and likely represents the untoward effects of environmental triggers on the genetically susceptible host.



Let's take a look at some of the symptoms of lupus.

Lupus on the outside



Synovitis



Malar rash



Painless oral ulcer



Raynaud's Phenomenon



Discoid rash



Jaccoud's arthropathy



Vasculitis



Alopecia

Lupus on the inside



Achiness, headache



Fatigue



Memory thief / brain fog



Depression


Illustrations of organs impacted by lupus



Serositis



Pericardial effusion




Cerebral infarct



Brain atrophy



Spherocytes



Glomerulonephritis

When to suspect lupus⁷

MOUTH

- Oral ulcers

LUNGS / HEART

- Serositis

KIDNEYS

- Proteinuria
- Hematuria

MUSCLE & JOINTS

- Arthritis
- Myositis

BRAIN

- Seizures
- Psychosis

SKIN


- Malar rash
- Discoid lesions
- Photosensitivity

BLOOD


- Low blood count

IMMUNOLOGIC

- Immunologic disorder
- Antinuclear antibodies (ANA)



Signs and symptoms (prevalent symptoms)





IVANA

Mostly external
symptoms


Michelle and Ivana are sisters,
but they have **different symptoms**,
with Ivana's being more external
and Michelle's more internal.



MICHELLE

Mostly internal
symptoms

Ivana and Michelle
describe the
differences in
their respective
symptoms.



Unfortunately, there is no gold-standard diagnostic test for lupus.

If you suspect lupus, you can order these tests:



CBC WITH DIFFERENTIAL, UA, RENAL FUNCTION PANEL

- Urine protein/creatinine ratio if any proteinuria.



ANTINUCLEAR ANTIBODY (ANA)

- Positive in vast majority of patients with SLE.
- Beware false positives!
- Higher titer more likely to be clinically significant.
- If ANA is positive, consider additional autoantibodies.
- Anti-dsDNA and/or anti-Smith – more specific but less sensitive.




COMPLEMENTS: C3, C4

- Often but not always low in active disease.
- Acute phase reactants: elevated in other causes of inflammation (infection).

The most common screen is for ANA— Antinuclear Antibodies.

The vast majority of women with lupus test positive for ANA, but a positive ANA test does not mean the person has lupus.

ANA could also indicate scleroderma, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis and other chronic conditions.



What do most lupus patients have in common?

Antinuclear Antibodies (ANA).

- Autoantibodies against various components of the cell nucleus.
- Present in other autoimmune illnesses, several infections, malignancies and in healthy people, as well.
- Sensitive (not specific for SLE)
- Because of low specificity, ANA usefulness increases if the pretest probability for lupus is high; i.e., the patient has symptoms and signs that can be attributed to SLE.
- Because of the high sensitivity of the ANA, a patient with negative ANA is unlikely to have lupus even when her/his clinical presentation is suggestive of lupus.

Autoantibodies in lupus

ANTIBODIES	LUPUS SPECIFICITY	LUPUS SENSITIVITY	CLINICAL ASSOCIATIONS
ANA	● ○ ○ Low	● ● ● High	
Anti-dsDNA	● ● ● High	● ● ○ Intermediate	Nephritis
Anti-Sm	● ● ● High	● ○ ○ Low	
Anti-RNP	● ○ ○ Low		Arthritis, myositis, lung disease
Anti-SSA	● ○ ○ Low		Dry eyes/mouth, subacute cutaneous lupus erythematosus (SCLE), neonatal lupus, photosensitivity
Anti-SSB	● ○ ○ Low		Same as above
Antiphospholipid	● ● ○ Intermediate	● ● ○ Intermediate ⁵	Clotting diathesis

So how do you determine whether to order an ANA?

If autoimmune rheumatic disease is likely, the ANA can be helpful for diagnosis and classification.

If autoimmune rheumatic disease is unlikely, do not order an ANA. A positive ANA may cause anxiety, unnecessary investigations and potential confusion for both patients and providers.

Example: For a given population of 100,000 AI/AN people

- 10%, or 10,000 individuals, will test positive with an ANA of 1:80
- 0.178%, 178 individuals, will have SLE in their lifetime
- That means $10,000 - 178 = 9,822$ people will test ANA positive, yet not have SLE.
- Yet nearly everyone with SLE will test ANA positive.
How can we improve the test performance? By only testing those individuals for whom we are highly suspicious for SLE



Labs to consider in patients with non-specific symptoms and low probability of lupus



LOOK FOR EVIDENCE OF KIDNEY DISEASE

- Urinalysis, urine protein/creatinine ratio.
- Can be done conveniently on random 'spot' urine protein and urine creatinine.



LOOK FOR (HEMOLYTIC) ANEMIA, THROMBOCYTOPENIA, LYMPHOPENIA, NEUTROPENIA

- CBC with differential white count.



CONSIDER CONFOUNDING COMORBIDITIES

- For example, fatigue and aches can be a sign of thyroid dysfunction. Consider checking a TSH.



IF HISTORY OF THROMBOEMBOLIC DISEASE OR RECURRENT MISCARRIAGES

- Consider antiphospholipid antibodies.

There are
significant disparities
in the diagnosis
and treatment
of lupus.



Lupus and mortality

Cardiovascular disease is the major cause of death in people with longstanding lupus.⁸

Factors contributing to increased mortality:

- Active lupus and infection
- High disease severity at diagnosis
- Younger age at diagnosis
- AI/AN, African American and Hispanic / Latino, Asian ethnicity
- Male gender
- Low socioeconomic status
- Poor adherence to treatment protocol
- Inadequate support system
- Limited education



Importance of early referral

- Mortality is higher in people with lupus compared to the general population.
- Five-year survival rate in 1953 was 50 percent. Today the survival rate is 90 percent because of better detection and treatment.
- Currently 80 to 90 percent of people with lupus survive 10 years after diagnosis, but that drops to 70 percent with advanced stages of organ deterioration.
- The leading causes of mortality are preventable with appropriate therapies.⁹



Providers must determine which symptoms of lupus to treat and which symptoms require the immediate attention of a rheumatologist.

Whether major organs are involved is a key determinant of the need to see a rheumatologist.



**Symptoms to be treated by provider
(less urgent referral)**

Non-major organs

- Arthritis
- Rashes
- Oral ulcers



**Symptoms to refer to a rheumatologist
(urgent referral)**

Major organs

- Glomerulonephritis
- CNS
- Pneumonitis
- Myocarditis
- Severe hematologic involvement

Let's look at a case study.

A 23-year-old AI/AN woman with no past medical history presented in the emergency department with these symptoms:

- Eight-week history of joint pain and swelling in hands, knees and ankles
- Fever
- Myalgias
- Pleuritic chest pain
- Weight loss
- Facial rash that worsened with sun exposure



She initially went to a local clinic and was treated for cellulitis with oral Keflex.

Two days before, she went to another emergency department. She had a temperature of 103°F and anemia. She was told it was a “viral syndrome” and discharged.



EXAM

- T 37.9°C
- BP 130/90
- Painless ulceration on the palate
- Malar rash
- Diffuse lymphadenopathy
- Synovitis of the MCP/PIP joints

LABS

Accumulated from various providers over time

- WBC 2.5×10^9 /L
- Total protein 9 g/dl
- Hgb 11g/dL
- Hct 32%
- BUN 11 mg/dL
- Cr .7 mg/dL
- ANA+
- Anti-dsDNA+
- Sm+



Should this person be referred to a rheumatologist?



Should this person be referred to a rheumatologist?

Yes.



What features in this case are concerning for lupus?

Let's look at another case study.

A woman from western Africa recently diagnosed with anemia, presumed but not confirmed to have iron-deficiency, visited her doctor **with these symptoms:**

- swelling of feet and hands
- non-specific rash on her face and arms
- swelling in joints
- enlarged lymph nodes
- generalized body aches
- sweating



CHART REVIEW REVEALS:

- Positive ANA of 1:1280
- 4.2 WBC with normal differential
- Hb/Hct is 9.7/30.4 MCV 77.3
- Plt 307



Should this person be referred to a rheumatologist?



Should this person be referred to a rheumatologist?

Yes.




What features in this case are concerning for lupus?

Attribution of symptoms to lupus is challenging and often requires

- First a certain level of suspicion (horses, not zebras) and
- Then a careful exam as well as history

As these patients often are frustrated and have seen other health care providers about their lupus symptoms.



Ivana on the
importance
of listening.



In summary



Early symptoms can be non-specific and be easily mistaken for other illnesses or syndromes.



Symptoms may be transient or prolonged and independent of one another.



Consider lupus if the person you are treating presents with vague complaints from the signs and symptoms list.



Also consider lupus if the person has a family history of autoimmune disease.



Consider Screening Labs: CBC, BMP, LFTs, ESR/CRP, TSH and UA. If appropriate, consider an ANA as well. If your suspicion for SLE remains high, refer to a rheumatologist.



Refer to a rheumatologist for assessment and diagnosis.

Working together toward diagnosis



Building trust is critical.



People from different cultural and socioeconomic backgrounds experience illness and treatment differently.



Physicians from different cultural and socioeconomic backgrounds perceive the people they are treating and their symptoms differently.



Through education, we can eliminate disparities in the time it takes AI/AN women to get diagnosed with lupus.

When the person you are treating is a woman of color in her childbearing years, lupus is not a zebra. It's a horse.

A call to action.



Referral to Rheumatology Process

Program Director/Fellow, please (1) delete this note and (2) insert the details for how and where to refer patients with suspected or diagnosed lupus.

Resources and Information

Ongoing care for people with lupus is a team effort, and it is a matter of life and death.

For presentations, videos, interactive case studies and CE/CME courses, visit The Lupus Initiative at TLItools.org/lectures.

We appreciate your participation in a post assessment.

Thank you.

Notes

1. Helmick CG, Felson DT, Lawrence RC et al. Arthritis Rheum. 2008; 58(1): 15–25; Chakravarty EF, Bush TM, Manzi S., Clarke AE, Ward MM. Arthritis Rheum. 2007; 57(7):2092–2094; Fessel WJ. Rheum Dis Clin North Am. 1988; 14(1): 15–23.
2. Ferucci ED et al. Prevalence and Incidence of Systemic Lupus Erythematosus in a Population-Based Registry of American Indian and Alaska Native People, 2007–2009, Sept 2014; 66(9):2494–2502
3. Lim SS, et al. The incidence and prevalence of systemic lupus erythematosus, 2002–2004: The Georgia Lupus Registry. Arthritis Rheumatol. 2014 Feb;77(2):357–78.
Somers EC, et al. Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. Arthritis Rheumatol. 2014 Feb;77(2): 379–78.
4. Kheir, JM, Gutheridge CJ Johnson JR, et al. Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus, Lupus Science & Medicine 2018; 5:e000247. doi:10.1136/lupus-2017-000247.
5. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol. 1995;22(7):1275–1270
6. Duran S, Apte M, Alarcon GS. J Natl Med Assoc. 2007;99(10):1197–1198; Ward MM, Pyun E, Studenski S. Arthritis Rheum. 1995;38(2):274–283; Alarcon GS, McGwin G Jr, Bastian HM, et al. Arthritis Rheum. 2001;45(2):191–202.
McCarty DJ, Manzi S, Medsger TA Jr, Ramsey-Goldman R, LaPorte RE, Kwok CK. Arthritis Rheum. 1995;38(9):1270–1270; Cooper GS, Parks CG, Treadwell EL, et al. Lupus. 2002;11(3):171–177
7. Tan EM, Cohen AS, Fries JF, et al. Arthritis Rheum. 1982;25:1271–1277. Hochberg MC. Arthritis Rheum. 1997;40:1725. [Letter].
8. Bernatsky S, Boivin JF, Joseph L. et al. Arthritis Rheum. 2007;54:2550–2557
9. American College of Rheumatology Ad Hoc Committee on Systematic Lupus Erythematosus. Guidelines for referral and management of systemic lupus erythematosus in adults. Arth Rheum 1999;42:1785–97